Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 10/20 | 0.62 |
| ▸ | CCNE1 | P24864 | 8/20 | 0.62 |
| ▸ | CDK2 | P24941 | 8/20 | 0.62 |
| ▸ | CDK7 | P50613 | 4/20 | 0.61 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.61 |
| ▸ | CLK1 | P49759 | 3/20 | 0.61 |
| ▸ | CLK2 | P49760 | 3/20 | 0.61 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.61 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.61 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.57 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.51 |
| ▸ | CDK9 | P50750 | 1/20 | 0.51 |
| ▸ | CCNH | P51946 | 1/20 | 0.51 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.51 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.51 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15941217 | 0.93 | CDK1 (0.58) | CDK1CCNE1CDK2CDK7CSNK1E | |
| SCHEMBL28037848 | 0.92 | CDK1 (0.62) | CDK1CCNE1CDK2CDK7CSNK1E | |
| SCHEMBL15940954 | 0.92 | CDK1 (0.64) | CDK1CCNE1CDK2CDK7CSNK1E | |
| SCHEMBL15941040 | 0.92 | CDK1 (0.62) | CDK1CCNE1CDK2CDK7CSNK1E | |
| SCHEMBL15941141 | 0.91 | CDK1 (0.62) | CDK1CCNE1CDK2CDK7CSNK1E | |
| SCHEMBL15941414 | 0.90 | CDK1 (0.62) | CDK1CCNE1CDK2CDK7CSNK1E | |
| SCHEMBL17352651 | 0.89 | CDK1 (0.64) | CDK1CCNE1CDK2CDK7CSNK1E | |
| SCHEMBL15940740 | 0.89 | CDK1 (0.64) | CDK1CCNE1CDK2CDK7CSNK1E | |
| SCHEMBL15941328 | 0.88 | CDK2 (0.62) | CDK1CCNE1CDK2CDK7CSNK1E | |
| SCHEMBL17352578 | 0.86 | CCNE1 (0.64) | CDK1CCNE1CDK2CDK7CSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150368248-A1 | 2-SUBSTITUTED-6-BIARYLMETHYLAMINO-9-CYCLOPENTYL-9H-PURINE DERIVATIVES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS | BIOPATTERNS S.R.O. (CZ) | 2015-12-24 | — | — | US | disclosed |
| EP-2953951-A2 | 2-SUBSTITUTED-6-BIARYLMETHYLAMINO-9-CYCLOPENTYL-9H-PURINE DERIVATIVES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS | Univerzita palackeho V Olomouci (CZ) | 2015-12-16 | — | — | EP | disclosed |
| CN-105026396-A | 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purine derivatives, use thereof as medicaments, and pharmaceutical compositions | UNIV PALACKEHO | 2015-11-04 | — | — | CN | disclosed |
| WO-2014121764-A2 | 2-SUBSTITUTED-6-BIARYLMETHYLAMINO-9-CYCLOPENTYL-9H-PURINE DERIVATIVES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2014-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368248-A1 | 2-SUBSTITUTED-6-BIARYLMETHYLAMINO-9-CYCLOPENTYL-9H-PURINE DERIVATIVES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS | ENTPD5, PNP, HCCS | CDK1 856/4885CCNE1 2605/4885CDK2 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.